Live Breaking News & Updates on தலை ஆஃப் மருந்து வளர்ச்சி
Stay updated with breaking news from தலை ஆஃப் மருந்து வளர்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Cabaletta Bio (CABA) Appoints Scott Brun, M.D. to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator Good day and thank you for standing by. Welcome to the Ironwood Pharmaceuticals First Quarter 2021 Investor Update Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Meredith Kaya, Vice President of Finance and Investor Relations. Please go ahead. Meredith Kaya Vice President, Finance and Investor Relations Good morning. And thanks for joining us for our first quarter 2021 investor update. Our press release crossed the wire this morning and can be found on our website. Today s call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current Safe Harbor statement slide as well as under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 and in our future SEC filings. Our forward-loo ....
Operator Ladies and gentlemen, thank you for standing by, and welcome to the Ironwood Pharmaceuticals Fourth Quarter and Full Year 2020 Investor Update Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Meredith Kaya. Thank you. Please go ahead. Meredith Kaya Vice President, Investor Relations and Corporate Communications Good morning, and thanks for joining us for our fourth quarter and full year 2020 investor update. Our press release crossed the wire this morning and can be found on our website. Today s call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. The discussion of these statements and risk factors is available on the current Safe Harbor statement slide as well as under the heading Risk Factors in our quarterly report on Form 10-Q for the quarter ended September 30, 2020 and i ....
5 February 2021 NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr Thomas Adams, Ph.D. as an executive director. Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company s pre-clinical and clinical drug development programs and associated intellectual property. Dr Thomas H Adams (age: 78) Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company. ....